Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610
In development [GID-TA10499] Expected publication date: TBC
In development [GID-TA10499] Expected publication date: TBC
In development [GID-TA10416] Expected publication date: TBC
In development [GID-TA10555] Expected publication date: TBC
In development [GID-TA10244] Expected publication date: TBC
In development [GID-TA10712] Expected publication date: TBC
In development [GID-TA10595] Expected publication date: TBC
In development [GID-TA10493] Expected publication date: TBC
In development [GID-TA10314] Expected publication date: TBC
In development [GID-TA10322] Expected publication date: TBC
In development [GID-TA10592] Expected publication date: TBC
In development [GID-TAG367] Expected publication date: 01 October 2014
In development [GID-TA10221] Expected publication date: TBC
In development [GID-TA10527] Expected publication date: TBC
In development [GID-TA10467] Expected publication date: TBC
In development [GID-TA10710] Expected publication date: TBC
In development [GID-TA10495] Expected publication date: 18 August 2021
In development [GID-TA10425] Expected publication date: 24 February 2021